Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study

Phase 2

Conditions: Colorectal Cancer

Interventions: Drug: Pemetrexed

First Posted Date: 2015-10-28

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 23

Registration Number: NCT02588781

Locations: 🇰🇷
Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)

Phase 3

Completed

Conditions: Non-Small-Cell Lung Carcinoma

Interventions: Biological: Pembrolizumab 200 mg
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed
Dietary Supplement: Folic acid 350-1000 μg
Dietary Supplement: Vitamin B12 1000 μg
Drug: Dexamethasone 4 mg
Drug: Saline solution

First Posted Date: 2015-10-19

Last Posted Date: 2024-07-09

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 616

Registration Number: NCT02578680

Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients

Phase 3

Conditions: Malignant Hydrothorax
Non Small Cell Lung Cancer

Interventions: Drug: Gemcitabine
Drug: Vinorelbine
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Oncorine
Drug: Cisplatin
Drug: Endostar

First Posted Date: 2015-10-19

Last Posted Date: 2016-10-21

Lead Sponsor: Xinqiao Hospital of Chongqing

Target Recruit Count: 134

Registration Number: NCT02579564

Avelumab in First-line NSCLC (JAVELIN Lung 100)

Phase 3

Completed

Conditions: First Line Non-Small Cell Lung Cancer

Interventions: Drug: Avelumab
Drug: Cisplatin
Drug: Pemetrexed
Drug: Paclitaxel
Drug: Avelumab Weekly
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2015-10-15

Last Posted Date: 2024-03-20

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 1214

Registration Number: NCT02576574

Locations: 🇧🇪
A.Z. Klina, Brasschaat, Belgium
🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇺🇸
Arizona Center for Cancer Care, Surprise, Arizona, United States

and more 344 locations

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Bevacizumab
Drug: Nivolumab
Other: Best Supportive Care
Drug: Erlotinib
Drug: Crizotinib
Drug: Pemetrexed
Drug: nab-Paclitaxel
Drug: Paclitaxel
Drug: Docetaxel
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2015-10-12

Last Posted Date: 2021-05-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 341

Registration Number: NCT02574078

Locations: 🇺🇸
Cancer Care Center, Bismarck, North Dakota, United States
🇺🇸
Lehigh Valley Hospital, Allentown, Pennsylvania, United States
🇺🇸
Texas Oncology Cancer Center - Sugar Land, Sugar Land, Texas, United States

and more 119 locations

Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer

Early Phase 1

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Carboplatin
Drug: Cisplatin
Drug: Docetaxel
Drug: Paclitaxel
Radiation: stereotactic radiosurgery

First Posted Date: 2015-10-05

Last Posted Date: 2017-01-31

Lead Sponsor: The Cooper Health System

Target Recruit Count: 22

Registration Number: NCT02568033

Locations: 🇺🇸
MD Anderson Cancer Center at Cooper, Camden, New Jersey, United States

Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Stage IV Lung Large Cell Carcinoma AJCC v7
Stage III Lung Non-Small Cell Cancer AJCC v7
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Stage IIIB Lung Large Cell Carcinoma AJCC v7
Stage IV Lung Adenocarcinoma AJCC v7
Stage III Lung Adenocarcinoma AJCC v7
Stage IV Lung Non-Small Cell Cancer AJCC v7
Stage III Lung Large Cell Carcinoma AJCC v7
Stage IIIA Lung Adenocarcinoma AJCC v7

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Cisplatin
Radiation: Intensity-Modulated Radiation Therapy
Drug: Methoxyamine
Drug: Methoxyamine Hydrochloride
Drug: Pemetrexed
Drug: Pemetrexed Disodium

First Posted Date: 2015-08-28

Last Posted Date: 2022-06-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT02535325

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy

Phase 2

Withdrawn

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: ADXS11-001
Drug: Pemetrexed

First Posted Date: 2015-08-25

Last Posted Date: 2023-12-19

Lead Sponsor: Advaxis, Inc.

Registration Number: NCT02531854

Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma

Phase 3

Conditions: Lung Neoplasms

Interventions: Drug: Gefitinib
Drug: Pemetrexed

First Posted Date: 2015-08-10

Last Posted Date: 2015-08-10

Lead Sponsor: Tang-Du Hospital

Target Recruit Count: 220

Registration Number: NCT02518802

Locations: 🇨🇳
Tangdu Hospital of the Fourth Millitary Medical University, Xi'an, Shaanxi, China

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Neuroendocrine Tumors
Small Cell Carcinoma
Ovarian Epithelial Cancer

Interventions: Drug: Cisplatin
Drug: RRx-001
Drug: Carboplatin
Drug: Etoposide
Drug: Paclitaxel
Drug: Doxil
Drug: Irinotecan
Drug: Nab-Paclitaxel
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Taxane
Drug: Pemetrexed

First Posted Date: 2015-07-03

Last Posted Date: 2022-10-03

Lead Sponsor: EpicentRx, Inc.

Target Recruit Count: 139

Registration Number: NCT02489903

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Baptist Health, Lexington, Kentucky, United States
🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy